-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

393 The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Myeloid Leukemia: Molecular Mutations and Their Prognostic Implications
Hematology Disease Topics & Pathways:
AML, Diseases, Pediatric, Biological Processes, Young Adult, Study Population, Clinically relevant, Myeloid Malignancies
Sunday, December 6, 2020: 1:15 PM

Eline J.M. Bertrums, MD1,2,3*, Jenny L. Smith, MSc, MEd4*, Rhonda E. Ries, MA4*, Todd A. Alonzo, PhD5*, Fabiana Ostronoff, MD4, Gertjan J.L. Kaspers, Prof. MD, PhD1, Henrik Hasle, MD6, Christian M. Zwaan1,2*, Betsy A Hirsch, PhD7*, Susana C. Raimondi, PhD8, Todd M. Cooper, DO9, Richard Aplenc, MD, PhD10, Alan S. Gamis, MD, MPH11, Edward A. Kolb, MD12, Bianca F. Goemans, MD, PhD1 and Soheil Meshinchi, MD, PhD13

1Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
2Department of Pediatric Oncology/Hematology, Erasmus Medical Center, Rotterdam, Netherlands
3Oncode Institute, Utrecht, Netherlands
4Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
5University of Southern California, Los Angeles, CA
6Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
7Children's Oncology Group, Monrovia, CA
8Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
9Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA
10Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
11Children's Mercy Kansas City, Kansas City, MO
12Division of Oncology, Nemours Alfed I. duPont Hospital For Children, Wilmington, DE
13Clinical Research Division, Fred Hutchinson Cancer Rsrch. Ctr., Seattle, WA


Cytogenetic and molecular aberrations are important prognostic factors in pediatric acute myeloid leukemia (AML). NUP98 translocations with more than 30 different partner genes have been identified in pediatric AML. The 2 most common fusions, NUP98-NSD1 and NUP98-KDM5A, have been shown to have distinct characteristics and are both associated with adverse outcomes. Although NUP98 fusions with less common fusion partners have been identified, the biological and clinical implications of these variants are unknown.


To determine the biological and clinical implications of the less common “other” NUP98 translocations (NUP98-X), we evaluated the clinical characteristics and transcriptome and genome sequencing data from 2396 children and young adults with AML within 4 consecutive Children’s Cancer Group (CCG) and Children’s Oncology Group (COG) trials CCG-2961, AAML03P1, AAML0531 and AAML1031. All NUP98-X translocations were confirmed by RNA sequencing.


Of the 2396 patients screened, 164 patients (6.8%) had a NUP98 translocation. We identified 20 patients with a NUP98­-X fusion (0.83%) and compared them with those with NUP98-NSD1 (n=110, 4.5%), NUP98-KDM5A (n=34, 1.4%), and a reference cohort without NUP98 translocations (n=2232). Translocation partners identified in the NUP98-X group were HOXA9 (n=4), HOXD13 (n=3), PHF15 (n=2), PHF23 (n=2), and single cases of BPTF, BRWD3, DDX10, HMGB3, HOXA13, KAT7, PRRX1, SET and TOP1. Besides the distinct characteristics of NUP98-NSD1 and NUP98-KDM5A, the NUP98-X group showed high inter-patient variance in clinical characteristics compared to our reference cohort. NUP98-X patients showed a clear bimodal age distribution with half of the patients being in the older age category and a similar number in the category <3 years (Figure 1). White blood cell count and blast percentages were in line with those of the reference cohort. We investigated the co-occurrence of common pediatric AML mutations within our cohort (Figure 2). There was a lack of additional driving mutations with the exception of WT1 mutations that are significantly more prevalent in the NUP98-X group compared to the reference cohort (25% vs 8%, p=0.018). NUP98-X patients with a WT1 mutation have a median age of 16.3 years compared to 2.3 years for those without a WT1 mutation. Also, in contrast to NUP98-NSD1 translocated patients, the co-occurrence of FLT3-ITD did not occur in NUP98-X translocated patients. Further, NUP98-X patients had a more varied transcriptome profile than did patients with NSD1 or KDM5A translocations (Smith J, et al. ASH abstract 2020).

We evaluated the impact of NUP98-X translocations in response to the initial induction therapy. The morphological complete remission (CR) rate after course 1 was 65% in the NUP98-X cohort versus 76% in the reference cohort (p=0.266). NUP98-NSD1 patients had an inferior CR rate (36%, p<0.001), but the CR rate in NUP98-KDM5A patients was similar (77%) to the reference cohort. Of all NUP98-X patients, 11% underwent stem cell transplantation (SCT), compared to 17% in the reference cohort, 40% in the NUP98-NSD1 and 23% in the NUP98-KDM5A cohort. Outcome analysis for NUP98-X patients demonstrated that despite differences in disease characteristics, they have similar adverse outcomes as patients with NSD1 or KDM5A translocations (Figure 3). Overall survival (OS) at 5 years from diagnosis was 35% compared to 65% in the group without NUP98 translocations (p=0.006, Figure 3). Event-free survival was 35% for NUP98-X patients, compared to 48% for those without NUP98 translocations (p=0.282). These adverse outcome rates are comparable to those reported in studies on high-risk pediatric AML patients.


NUP98-X translocated pediatric AML patients represent a rare cohort with a high variability in both translocation partners and other clinical characteristics. Despite this heterogeneity, the OS of these patients is comparable to high-risk pediatric AML patients, which justifies a high-risk stratification of these patients and emphasizes the need for developing new treatment strategies. Further research within large patient cohorts is needed to investigate the biologic and clinical characteristics of these rare translocations and potential differences between the different NUP98-X fusion partners.

Disclosures: Kaspers: AbbVie: Ended employment in the past 24 months; Helsinn Healthcare: Ended employment in the past 24 months; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees; Janssen R&D: Ended employment in the past 24 months. Cooper: Celgene: Other: Spouse was an employee of Celgene (through August 2019).

<< Previous Abstract | Next Abstract
*signifies non-member of ASH